AddLife stock
ALIF-B.STSTOAddLife AB (publ), HealthcareISIN SE0014401378
58Score 58 out of 100, Neutral
Price and trend
78 / 100
Price history
−3.7% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 15% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 4.7% below its 52-week high. Largest decline in 11 years: 86% (September 2021 to October 2023).
Chart figures for advanced users
- SMA 50$17.37
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.83
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.50
- The lowest closing price of the last twelve months.
- Resistance$19.11
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- AddLife AB (publ) belongs to the Medical (Instruments & Supplies) industry (Sweden) and, with a market value of $2.14B, is number 31 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.05B (up 1.5% year on year) and earnings of $56.15M (up 122.2%).
- For fiscal 2026, analysts expect on average revenue of $1.1B (up 5.2%) and adjusted earnings per share of $0.46 (down 30.7%).
Show more
- MEQIRI Score 58 out of 100 (Neutral): rank 291 of 702 in Healthcare, median 53.
- The P/E is 34.4 (Medical (Instruments & Supplies) median 34.6, own median of recent years 35.8).
- Our model puts fair value at $14.69, with the price 24% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 175% of earnings over the last 12 months.Fundamentals 84
- Consistently profitableProfit in all 10 fiscal years from 2015 to 2025.Fundamentals 84
- Growing faster than its industryRevenue up 14.6% a year since 2020, Medical (Instruments & Supplies) median 9.5%.Growth 59
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and technical analysis, while valuation and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 59 to 58.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $11.30 and expensive above $20.98 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $11.07 (cash-flow model) and $18.31 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $13.82, at 6.2% it would be $15.99.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 1.6% on the twelve months before. Revenue has grown strongly since 2012, at around 23% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 38%, operating 7%, net 5%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 3 Feb 2027in 82 days
- Last reported
- 21 Oct 2026EPS reported $0.10 (expected $0.09)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 3.4% since 15 Oct 2026.
- Earnings per share
- $0.46+3.4%
- Revenue
- $1.1B+0.2%
- Earnings per share
- $0.57+0.5%
- Revenue
- $1.2B+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at AddLife
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Pulse BiosciencesPLSE $3.84B46
- SCHOTT Pharma AG & Co. KGaA1SXP.F $3.63B70
- Carl Zeiss MeditecAFX.DE $3.34B64
- AtriCureATRC $2.85B51
- Bonesupport HoldingBONEX.ST $2.07B72
- AzentaAZTA $1.92B50
- SKAN GroupSKAN.SW $1.87B72
- DENTSPLY SIRONAXRAY $1.84B46
ETFs that hold AddLife
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares OMX Stockholm Capped UCITS ETFOM3X | 0.25% | 0.10% | €198.93M |
| WisdomTree Europe SmallCap Dividend UCITS ETFWTES | 0.16% | 0.38% | €86.74M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.12% | 0.30% | €3.45B |
Show 5 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.12% | 0.23% | €321.86M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.07% | 0.30% | €813.64M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.03% | 0.10% | €395.74M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.02% | 0.35% | €8.27B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 22 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.